北京時間2023年03月13日21時48分，美國OTC市場Northwest Biotherapeutics Inc（NWBO.us）股票出現波動，股價急速下跌5.33%。截至發稿，該股報0.568美元/股，成交量4.8073萬股，換手率0.00%，振幅5.00%。
最近的業績數據顯示，該股實現營業收入1.68百萬美元，淨利潤-1.05億美元，每股收益-0.10美元，毛利135000.00美元，市盈率-5.66倍。
機構評級方面，目前暫無機構對該股做出“買入、持有、賣出”建議。
美國OTC市場Northwest Biotherapeutics Inc股票所在的生物技術行業中，整體漲幅爲2.11%。其相關個股中，Provention Bio Inc、Calliditas Therapeutics Ab、Clearmind Medicine Inc漲幅較大，Tenax Therapeutics Inc、Clearmind Medicine Inc、Aridis Pharmaceutical Inc較爲活躍，換手率分別爲%、%、%，振幅較大的相關個股有Pasithea Therapeutics Corp C/Wts 12/08/2026 (To Pur Com)、Lipocine Inc、Eqrx Inc C/Wts 17/12/2026 (To Pur Com)，振幅分別爲%、%、%。
美國OTC市場Northwest Biotherapeutics Inc公司簡介：Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
（以上內容爲自選股智能機器寫手Money Call完成，僅作爲用戶看盤參考，不作爲交易依據。）